Pleiotropic effects of the sirtuin inhibitor sirtinol involves concentration-dependent modulation of multiple nuclear receptor-mediated pathways in androgen-responsive prostate cancer cell LNCaP

Molecular Carcinogenesis

Volumn 52, Issue 9, 2013, Pages 676-685

  Wang, Thomas T Y ^a   Schoene, Norberta W ^a   Kim, Eun Kyung ^b   Kim, Young S ^b  

^a BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen; Estrogen; Insulin like growth factor 1; Sirtinol; Sirtuin; Xenobiotic metabolism

Indexed keywords

3,3' DIINDOLYLMETHANE; ANDROGEN; CELL NUCLEUS RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOCHROME P450 1A1; ESTROGEN; GENISTEIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RESVERATROL; SIRTINOL; SOMATOMEDIN C;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; DRUG STRUCTURE; HUMAN; HUMAN CELL; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

ANDROGEN; ESTROGEN; INSULIN-LIKE GROWTH FACTOR-1; SIRTINOL; SIRTUIN; XENOBIOTIC METABOLISM;

ANDROGENS; ANTICARCINOGENIC AGENTS; BENZAMIDES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHROME P-450 CYP1A1; ESTROGENS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOLS; PHYTOTHERAPY; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SIRTUINS; UP-REGULATION;

EID: 84881613507     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21906     Document Type: Article

References (30)

1. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276: 38837-38843.
2. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006; 126: 257-268.
3. Marmorstein R. Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases. Biochem Soc Trans 2004; 32: 904-909.
4. Michan S, Sinclair D. Sirtuins in mammals: Insights into their biological function. Biochem J 2007; 404: 1-13.
5. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem 2006; 75: 435-465.
6. Laurenson P, Rine J. Silencers, silencing, and heritable transcriptional states. Microbiol Rev 1992; 56: 543-560.
7. Gartenberg MR. The Sir proteins of Saccharomyces cerevisiae: Mediators of transcriptional silencing and much more. Curr Opin Microbiol 2000; 3: 132-137.
8. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000; 14: 1021-1026.
9. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800.
10. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001; 98: 15113-15118.
11. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196.
12. Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005; 280: 17038-17045.
13. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009; 284: 3823-3832.
14. Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009; 10: 18-25.
15. Köhle C, Bock KW. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol 2007; 73: 1853-1862.
16. Wang TT, Milner MJ, Milner JA, Kim YS. Estrogen receptor alpha as a target for indole-3-carbinol. J Nutr Biochem 2006; 17: 659-664.
17. Wang TT, Schoene NW, Kim YS, Mizuno CS, Rimando AM. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol Nutr Food Res 2010; 54: 335-344.
18. Takahashi Y, Hursting SD, Perkins SN, Wang TC, Wang TT. Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Mol Carcinog 2006; 45: 18-25.
19. Payton-Stewart F, Schoene NW, Kim YS, et al. Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP. Mol Carcinog 2009; 48: 862-871.
20. Hong C, Kim HA, Firestone GL, Bjeldanes LF. 3, 3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002; 23: 1297-1305.
21. Fabiani R, Rosignoli P, De Bartolomeo A, Fuccelli R, Morozzi G. Inhibition of cell cycle progression by hydroxytyrosol is associated with upregulation of cyclin-dependent protein kinase inhibitors p21(WAF1/Cip1) and p27(Kip1) and with induction of differentiation in HL60 cells. J Nutr 2008; 138: 42-48.
22. Takahashi Y, Perkins SN, Hursting SD, Wang TT. 17beta-Estradiol differentially regulates androgen-responsive genes through estrogen receptor-beta- and extracellular-signal regulated kinase-dependent pathways in LNCaP human prostate cancer cells. Mol Carcinog 2007; 46: 117-129.
23. Hill R, Bodzak E, Blough MD, Lee PW. p53 Binding to the p21 promoter is dependent on the nature of DNA damage. Cell Cycle 2008; 7: 2535-2543.
24. Jung-Hynes B, Ahmad N. Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle 2009; 8: 1478-1483.
25. Thakur VS, Gupta K, Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis 2012; 33: 377-384.
26. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002; 179: 1-14.
27. Monzavi R, Cohen P. IGFs and IGFBPs: Role in health and disease. Best Pract Res Clin Endocrinol Metab 2002; 16: 433-447.
28. Massoner P, Colleselli D, Matscheski A, et al. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: Inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 2009; 16: 795-808.
29. Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006; 25: 176-185.
30. Takahashi Y, Lavigne JA, Hursting SD, et al. Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: A comparison study using DNA microarray. Mol Carcinog 2006; 45: 943-956.